Disease · MONDO_0016684

anaplastic astrocytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anaplastic astrocytoma. Diseases, record MONDO_0016684. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016684

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anaplastic astrocytoma; Open Targets
Open Targets ID: MONDO_0016684; Open Targets
Other names: astrocytoma, anaplastic, malignant, grade III astrocytic neoplasm, grade III astrocytic tumor, grade III astrocytic tumour, grade III astrocytoma, malignant astrocytoma; Open Targets
Disease Ontology: DOID:3078; Disease Ontology
NCI Thesaurus: C9477; NCI Thesaurus
Orphanet: ORPHA:251589; Orphanet
Highest stage of its drugs: Approval, for 1 of its 63 drugs, from PMDA; Open Targets

Drugs63

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROCARBAZINE HYDROCHLORIDE	CHEMBL1200410	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	25	25	25	Drugs and targets
CARMUSTINE	CHEMBL513	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CINTREDEKIN BESUDOTOX	CHEMBL2108583	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PORFIMER SODIUM	CHEMBL1201481	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRABEDERSEN	CHEMBL2108345	Oligonucleotide	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
EFLORNITHINE	CHEMBL830	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MITOLACTOL	CHEMBL2104612	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 63

See all 63 drugs

Targets105

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP1	DNA topoisomerase 1	4	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	3	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3065	Drugs and targets

1 to 10 of 105

See all 105 targets

Trials77

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00004259	Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas	Phase 3	230	2017-11-13	Brain and Central Nervous System Tumors	CARMUSTINE, LOMUSTINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03224104	Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.	Phase 1	71	2025-11-26	Astrocytoma, Grade III, Glioblastoma	TEMOZOLOMIDE, ZOTIRACICLIB	Its record names the disease	ClinicalTrials.gov
NCT02942264	Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma	Phase 1/2	53	2021-09-28	Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma	TEMOZOLOMIDE, ZOTIRACICLIB	Its record names the disease	ClinicalTrials.gov
NCT00589875	Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma	Phase 2	52	2024-04-03	Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma	AGLATIMAGENE BESADENOVEC, VALACYCLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00859222	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	Phase 1/2	51	2016-11-28	Malignant Glioma	BEVACIZUMAB, PANOBINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02781792	Temozolomide Chronotherapy for High Grade Glioma	Phase 2	42	2025-06-27	Glioma, Glioblastoma Multiforme	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01466686	Low Dose Radiation Therapy for Glioblastoma Multiforme	Phase 2	31	2023-07-03	High Grade Glioma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00606008	A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma	Phase 2	30	2012-10-31	Anaplastic Astrocytoma, Glioblastoma	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00761280	Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma	Phase 3	27	2014-08-22	Anaplastic Astrocytoma, Glioblastoma	CARMUSTINE, LOMUSTINE, TEMOZOLOMIDE, TRABEDERSEN	Its record names the disease	ClinicalTrials.gov
NCT01663012	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma	Phase 2	20	2015-06-11	Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)	ETIRINOTECAN PEGOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 77

See all 77 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm 1: Temozolomide Morning vs Arm 2: Temozolomide Evening: deaths from any cause	7 of 22	6 of 20	42	NCT02781792	Trial comparisons
Arm 1: Temozolomide Morning vs Arm 2: Temozolomide Evening: serious adverse events	6 of 22	5 of 20	42	NCT02781792	Trial comparisons
Arm 1: Temozolomide Morning vs Arm 2: Temozolomide Evening: Feasibility of Patient Treatment Compliance as Measured by Number of Participants Who Were at Least 80% Compliance With Assigned Administration Time	17 of 17	15 of 15	32	NCT02781792	Trial comparisons
Trabedersen 10 µM vs Chemotherapy: serious adverse events	6 of 13	0 of 11	24	NCT00761280	Trial comparisons
AXL1717, 400mg Initial Dose vs AXL1717, 300mg Initial Dose: Phase I Subjects - Imaging Evidence of Response.	0 of 2	5 of 7	9	NCT01721577	Trial comparisons
Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: The Number of Participants With Adverse Events	4 of 4	2 of 3	7	NCT00047879	Trial comparisons
Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: serious adverse events	3 of 4	2 of 3	7	NCT00047879	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30883662	RESULT	1	PubMed
26843484	RESULT	1	PubMed
25572329	RESULT	1	PubMed
24786603	RESULT	1	PubMed
24380758	RESULT	1	PubMed
21984064	RESULT	1	PubMed
21844505	RESULT	1	PubMed
21547395	RESULT	1	PubMed
20143438	RESULT	1	PubMed
18824712	RESULT	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016684

GET https://conductscience.org/api/diseases/v1/MONDO_0016684/drugs?page=2

API reference For AI assistants